Vimarsana
Biggest News Aggregation in the World

Page 9 - Dermatologic Surgery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dermatologic Surgery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dermatologic Surgery Today - Breaking & Trending Today

Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-dose Administration of Botulinum Toxin - Vimarsana News

Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-dose Administration of Botulinum Toxin

High-dose Jeuveau, with a dosage double that of the existing 20 units, has succeeded in Phase 2 clinical trials as Extra StrengthDemonstrating a proven long-term efficacy of 6 months or 26 weeks, Jeuveau enhances global product competitiveness by

The 10 Best Hair Removal Creams of 2023, Tested and Reviewed - Vimarsana News

The 10 Best Hair Removal Creams of 2023, Tested and Reviewed

We tested 22 hair removal creams, evaluating them on consistency, application, and effectiveness. After weeks of testing, these are the best hair removal creams of 2023

Source: shape.com
Sharps Injuries Are Common Among Mohs Surgeons, Survey Finds - Vimarsana News

Sharps Injuries Are Common Among Mohs Surgeons, Survey Finds

Among respondents who sustained a sharps injury, 44.1% did not report them.

The Alma TED Treatment Made My Thinning Hair 10 Times Thicker - Vimarsana News

The Alma TED Treatment Made My Thinning Hair 10 Times Thicker

The FDA-approved Alma TED is thought to be a less-invasive alternative to PRP. Beauty editor Samantha Holender reviews the treatment.

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U - Vimarsana News

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U

Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022Raises Full-Year 2023 Net Revenue Guidance from $185 to $195 Million to $194 to $198 MillionOperating Use of Cash in Q3 of $0.9 Million, Demonstrating Continued Progress Towards Achieving Profitability1 with Existing Liquidity“Extra-Strength...